Gregory Lumpkin is the Founder of GML & Associates, a firm that provides financial and accounting services for emerging companies. Mr. Lumpkin has served as interim CFO for a number of start-up biotechnology companies, including Tarsa Therapeutics, Cortria Corporation, Tobira Therapeutics and sGC Pharma. Prior to starting GML & Associates in 2006, Mr. Lumpkin was vice president of finance and administration with Vitae Pharmaceuticals, a NASDAQ-listed biopharmaceutical company dedicated to discovering, developing, and commercializing small molecule drugs in a variety of therapeutic areas. He previously served as the CFO and vice president of business development of Interlace (formerly PanamaTech), a privately held B2B integration and transaction management services company. Prior to Interlace, Mr. Lumpkin served as the director of finance and accounting for Pharmacopeia, Inc., a NASDAQ-listed pharmaceutical biotechnology company, and as the director of finance, production, and administration for Quantix Systems, a privately held environmental diagnostic biotechnology company. In addition, Mr. Lumpkin held several accounting and financial positions at McGraw Hill.
Mr. Lumpkin acts as the Vice President of Finance partnering with WindMIL’s senior leadership team to provide insight and recommendations for the achievement of both short and long term company goals while being primarily responsible for WindMIL’s financial analysis, budget, forecast, cash management, accounting and tax operations.